Residuals of Model 4










R2 (bigger is better)
Model
0.26
0.28
0.30
RMSE (smaller is better)
Model
13.4
13.5
13.6
13.7
13.8
13.9
RSS (smaller is better)
Model
1300000
1400000
1500000
1600000
1700000
Model
Dataset
Development
Validation


A
B
Favours GLP1
Favours SGLT2
Number of people
1000
500
0
750
250
−10
0
10
20
HbA1c difference (mmol/mol)


A
Male
Favours GLP1
Favours SGLT2
Number of people
0
300
600
900
−10
0
10
20
HbA1c difference (mmol/mol)
Female
Favours GLP1
Favours SGLT2
Number of people
0
200
400
600
−10
0
10
20
HbA1c difference (mmol/mol)
B
Male
Favours GLP1
Favours SGLT2
Number of people
0
200
400
600
−10
0
10
20
HbA1c difference (mmol/mol)
Female
Favours GLP1
Favours SGLT2
Number of people
0
100
200
300
−10
0
10
20
HbA1c difference (mmol/mol)

Effects validation lm(hba1c~drugclass+prop_score)



Effects validation prop score matching




Effects validation prop score inverse weighting
A
B
Decile average treatment effect
Predicted conditional average treatment effec
−12 −10 −8 −6 −4 −2 0 2 4 6 8 10